GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Price-to-Free-Cash-Flow

Artgen Biotech PJSC (MIC:ABIO) Price-to-Free-Cash-Flow : 75.15 (As of May. 25, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC Price-to-Free-Cash-Flow?

As of today (2024-05-25), Artgen Biotech PJSC's share price is ₽103.10. Artgen Biotech PJSC's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was ₽1.37. Hence, Artgen Biotech PJSC's Price-to-Free-Cash-Flow Ratio for today is 75.15.

The historical rank and industry rank for Artgen Biotech PJSC's Price-to-Free-Cash-Flow or its related term are showing as below:

MIC:ABIO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 16.56   Med: 107.42   Max: 317.54
Current: 78.54

During the past 13 years, Artgen Biotech PJSC's highest Price-to-Free-Cash-Flow Ratio was 317.54. The lowest was 16.56. And the median was 107.42.

MIC:ABIO's Price-to-Free-Cash-Flow is ranked worse than
73.46% of 211 companies
in the Biotechnology industry
Industry Median: 31.69 vs MIC:ABIO: 78.54

Artgen Biotech PJSC's Free Cash Flow per Share for the six months ended in Jun. 2023 was ₽-0.14. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was ₽1.37.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Artgen Biotech PJSC was 49.90% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 97.50% per year.

During the past 13 years, Artgen Biotech PJSC's highest 3-Year average Free Cash Flow per Share Growth Rate was 97.50% per year. The lowest was -50.90% per year. And the median was -2.70% per year.


Artgen Biotech PJSC Price-to-Free-Cash-Flow Historical Data

The historical data trend for Artgen Biotech PJSC's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC Price-to-Free-Cash-Flow Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 103.10 - 72.08 63.91

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 72.08 - 63.91 -

Competitive Comparison of Artgen Biotech PJSC's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Artgen Biotech PJSC's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artgen Biotech PJSC's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Artgen Biotech PJSC's Price-to-Free-Cash-Flow falls into.



Artgen Biotech PJSC Price-to-Free-Cash-Flow Calculation

Artgen Biotech PJSC's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=103.10/1.372
=75.15

Artgen Biotech PJSC's Share Price of today is ₽103.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was ₽1.37.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Artgen Biotech PJSC  (MIC:ABIO) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Artgen Biotech PJSC Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Artgen Biotech PJSC (MIC:ABIO) Business Description

Traded in Other Exchanges
N/A
Address
Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.